Shuhei Hosomi, Yu Nishida, Yasuhiro Fujiwara. Efficacy of Upadacitinib as a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series. Internal medicine (Tokyo, Japan). 2023
Yasuhiro Fujiwara, Akinari Sawada, Akira Higashimori, Rieko Nakata, Kojiro Tanoue, Yu Nishida, Hirotsugu Maruyama, Masaki Ominami, Shusei Fukunaga, Koji Otani, et al. The impact of COVID-19 on Japanese patients with eosinophilic gastrointestinal disorders during the vaccination era. JGH open : an open access journal of gastroenterology and hepatology. 2023. 7. 10. 702-707
Yu Nishida, Shuhei Hosomi, Yumie Kobayashi, Rieko Nakata, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, et al. Impact of the COVID-19 Pandemic on the Lifestyle and Psychosocial Behavior of Patients with Inflammatory Bowel Diseases: A Narrative Review. Healthcare (Basel, Switzerland). 2023. 11. 19
Hiroaki Okuda, Shuhei Hosomi, Shigehiro Itani, Noriyuki Kurimoto, Yumie Kobayashi, Rieko Nakata, Yu Nishida, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, et al. Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease. Journal of gastroenterology and hepatology. 2023. 38. 6. 910-920
Noriyuki Kurimoto, Yu Nishida, Shuhei Hosomi, Shigehiro Itani, Yumie Kobayashi, Rieko Nakata, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, et al. Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing. PloS one. 2023. 18. 1. e0280252
Thioprines are essential following oral tacrolimus induction therapy for patients with ulcerative colitis
(Asian organization for crohn's and colitis 2018)
Serum interleukin-6 predicts future outcomes of infliximab for ulcerative colitis
(13th congress of european crohn's and colitis organization (ECCO) 2018)
Serum interleukin-6 level predicts short-term clinical response of anti-tumor nercrosis factor therapy in patients with ulcerative colitis
(AGA 2017 2017)